Atomoxetine in the Treatment of Binge Eating Disorder

• Status: Completed
• Trial end date: 2007-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The specific aim of this study is to assess the efficacy and safety of atomoxetine compared with placebo in outpatients with binge eating disorder.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Lindner Center of HOPE
• Collaborator: University of Cincinnati
• Treatments: Atomoxetine Hydrochloride

Criteria

Inclusion Criteria:

• Subjects will meet the DSM-IV criteria for a diagnosis of binge-eating disorder for at least the last 6 months

• In addition, subjects will report at least 3 binge eating episodes per week for the last 6 months prior to randomization

Exclusion Criteria:

• Have concurrent symptoms of bulimia nervosa or anorexia nervosa

• Women who are pregnant, lactating, or of child bearing potential who are not using adequate contraceptive measures

• Patients who are displaying clinically significant suicidality or homicidality